# A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting

> **NCT02493777** · PHASE3 · COMPLETED · sponsor: **Ironshore Pharmaceuticals and Development, Inc** · enrollment: 125 (actual)

## Conditions studied

- Attention Deficit Hyperactivity Disorder

## Interventions

- **DRUG:** HLD200 methylphenidate hydrochloride (MPH) Capsules
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02493777
- **Lead sponsor:** Ironshore Pharmaceuticals and Development, Inc
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07
- **Primary completion:** 2016-02
- **Final completion:** 2016-03
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02493777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02493777, "A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02493777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*